Functional Neuromodulation Ltd. (FNM) is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with Alzheimer’s and other memory and cognitive disorders. The company, founded in 2010 by Andres Lozano, MD, scientific founder and principal inventor is investigating the use of DBS of the fornix (DBSf) to drive neural activity and modulate the brain’s memory circuit. FNM investors include Genesys Capital, Foundation Medical Partners and Medtronic, Inc. The company has recently reported 12-month results of the ADvance Study, a multi-center feasibility study of DBSf in 42 patients with mild Alzheimer’s disease. The ADvance Study is also supported through a translational grant of up to $2.75M from the National Institute on Aging, part of the National Institutes of Health.
CAUTION — Investigational device. Limited by Federal law to investigational use.
Functional Neuromodulation, Ltd. | 2 Oliver St., Suite 61 | Boston, MA 02109 | email@example.com | 1-866-296-4040
© 2015 Functional Neuromodulation Ltd. All rights reserved.